A study of 149 women with platinum sensitive ovarian cancer, half treated with carboplatin and paclitaxel or gemcitabine, half with that treatment plus pertuzumab, showed that the addition of pertuzumab to chemotherapy did not significantly increase progression free survival (PFS). However, the drug was described as “well-tolerated” and did not appear to increase the risk of cardiac events.
Read the abstract here
A research team, led by Dr. Ugo Cavallaro and supported by OCRA’s 2019 Collaborative Research Development Grant, made progress toward improving immunotherapies for ovarian cancer. Dr. Frances R. Balkwill, a … Continued
Leaders in the patient advocacy space came together for a wide-ranging study on the often-overlooked challenges faced by caregivers of cancer patients, with Tracy Moore, LCSW, who serves as Ovarian … Continued
A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, … Continued
Get email updates about research news, action alerts, and ways to join the fight.
